Results 131 to 140 of about 585,196 (339)

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia   +20 more
wiley   +1 more source

Prolonged persistence of IgM against dengue virus detected by commonly used commercial assays

open access: yesBMC Infectious Diseases, 2018
Background Initial symptoms of dengue fever are non-specific, and thus definite diagnosis requires laboratory confirmation. Detection of IgM against dengue virus (DENV) has become widely used for dengue diagnosis.
Yu-Wen Chien   +7 more
doaj   +1 more source

Solid-phase radioimmunoassay of rubella virus immunoglobulin G and immunoglobulin M antibodies [PDF]

open access: green, 1976
Kirsti Kalimo   +6 more
openalex   +1 more source

Digital Activity Markers in Chronic Inflammatory Demyelinating Polyneuropathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the utility of smartwatch and smartphone‐based activity metrics for assessing disease severity and quality of life in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Methods In the electronic monitoring of disease activity in patients with CIDP (EMDA‐CIDP) trial, we performed a prospective ...
Lars Masanneck   +15 more
wiley   +1 more source

Efgartigimod Combined With Steroid Treatment for HAM/TSP: A Case Report

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive neurological disorder with limited treatment options. We report a 54‐year‐old female with decade‐long, progressive HAM/TSP, previously refractory to rituximab, who experienced worsening spastic paraparesis and neurogenic bladder dysfunction.
Jiahui Zeng   +5 more
wiley   +1 more source

The Effect of Six Weeks of High-Intensity Interval Training With Zinc Supplementation on Some Humoral Immunity Markers in Female Futsal Players

open access: yesAnnals of Applied Sport Science, 2018
Background. It seems strenuous trainings have a suppressing effect on the immune function and athletes performing such trainings are probably prone to infectious diseases due to weakened immune system. Objectives. The aim of this study was to examine the
Malihe Saeedy   +2 more
doaj  

Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT In this multicenter retrospective cohort study of 135 people with aquaporin‐4 IgG+ neuromyelitis optica spectrum disorder (NMOSD), some of whom were exposed to multiple therapies, we evaluated the effectiveness and tolerability of rituximab (n = 111) and novel monoclonal antibodies (nMAbs): eculizumab (n = 9), inebilizumab (n = 23), and ...
Zarmina Javed   +9 more
wiley   +1 more source

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy